Global mRNA Therapeutics CDMO Market 2025–2029: Competitive Insights and Opportunities

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Global Market Value Of The mRNA Therapeutics CDMO Industry In 2025?

The mRNA therapeutics CDMO market has witnessed significant expansion in recent years. This market is projected to increase from $4.24 billion in 2024 to $4.74 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 12.0%. Historically, this growth can be ascribed to a rising demand for rapid vaccine development, enhanced public and private funding for mRNA research, an increasing prevalence of infectious diseases, the expansion of pharmaceutical outsourcing practices, and a stronger global focus on pandemic preparedness.

The mRNA therapeutics CDMO market is projected to undergo rapid expansion in the coming years. It is expected to reach $7.40 billion by 2029, growing at a compound annual growth rate (CAGR) of 11.8%. The projected growth is driven by a heightened emphasis on personalized medicine, increasing need for quick response platforms against new diseases, rising healthcare spending in emerging economies, expanding government support for local manufacturing, and growing interest in non-infectious disease applications. Significant trends for the forecast period include advancements in lipid nanoparticle delivery technologies, increased automation in production, broader implementation of modular and continuous manufacturing systems, improvements in cold chain logistics infrastructure, and greater integration of artificial intelligence for process optimization.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25841&type=smp

Which Drivers Are Supporting Growth Of The mRNA Therapeutics CDMO Market?

The increasing prevalence of chronic and infectious diseases is anticipated to drive the expansion of the mRNA therapeutics CDMO market in the future. These diseases include lasting health issues like diabetes, cardiovascular problems, and asthma, along with ailments triggered by harmful microbes such as viruses, bacteria, and parasites, capable of direct or indirect transmission between people. The rise in chronic and infectious diseases is linked to an aging global population, which is more prone to both enduring health conditions and infections. The mRNA therapeutics CDMO sector aids in tackling chronic and infectious diseases through comprehensive development and manufacturing services, expediting the provision of targeted, personalized mRNA treatments to patients. For example, data from Allergy UK, a national charity based in the UK, indicated in April 2024 that over 21 million people in the UK suffer from allergies, which was identified as the most frequently reported chronic health condition in 2022, with forecasts suggesting that by 2026, half of Europe’s population will encounter at least one allergy. Consequently, the escalating impact of chronic and infectious diseases is stimulating the expansion of the mRNA therapeutics CDMO market.

What Are The Different Segment Classifications Within The mRNA Therapeutics CDMO Market?

The mrna therapeutics cdmo market covered in this report is segmented –

1) By Type Of Service: Development Services, Manufacturing Services, Laboratory Services

2) By Indication: Infectious Diseases, Metabolic And Genetic Diseases, Cardiovascular And Cerebrovascular Diseases

3) By Application: Viral Vaccines, Protein Replacement Therapies, Cancer Immunotherapies

4) By End User: Pharmaceutical Companies, Biotechnology Companies, Academic Institutions, Research Organizations

Subsegments:

1) By Development Services: Process Development, Analytical Method Development, Formulation Development, Regulatory Support

2) By Manufacturing Services: Plasmid DNA Manufacturing, mRNA Synthesis, Lipid Nanoparticle (LNP) Formulation, Fill-Finish Services

3) By Laboratory Services: Quality Control Testing, Stability Testing, Bioanalytical Testing, Preclinical Testing

What Long-Term Trends Will Shape The Future Growth Of The mRNA Therapeutics CDMO Industry?

Key companies operating within the mRNA therapeutics CDMO market are concentrating on developing advanced solutions, such as in situ nanomedicine vaccines, to boost the effectiveness and precision of mRNA-based vaccines through focused immune stimulation. An in situ nanomedicine vaccine is an advanced mRNA-based therapeutic crafted to produce nanomedicines inside the patient’s system, enabling targeted administration and personalized immune activation via engineered transgene expression. For example, in January 2025, Esphera SynBio Inc., a Canada-based biotechnology firm, commenced a new project with support from the CQDM Quantum Leap program. This initiative aims to refine first-generation lipid nanoparticle or messenger RNA (LNP/mRNA) vaccines by incorporating proprietary transgene designs that induce the in vivo production of immunostimulatory nanomedicines. This strategy facilitates precise antigen delivery and tailored immune responses, marking the technology as a potential game-changer in vaccine development.

Which Global Market Leaders Are Shaping The Future Of The mRNA Therapeutics CDMO Sector?

Major companies operating in the mrna therapeutics cdmo market are Sanofi SA, Thermo Fisher Scientific Inc., Boehringer Ingelheim, Danaher Corporation, Merck KGaA, FUJIFILM Holdings Corporation, Evonik Industries AG, BioNTech SE, AGC Biologics GmbH, Eurofins Scientific SA, Samsung Biologics Co. Ltd., Wuxi Biologics, Recipharm AB, EMERGENT BioSolutions Inc., Genscript Biotech, Novo Holdings AS, Ginkgo Bioworks Holdings Inc., Corden Pharma Corp., CureVac SE, TriLink BioTechnologies LLC, Biocina Pty Ltd., Aldevron LLC, Synbio Technologies LLC, etherna manufacturing, Bio-Synthesis Inc., Biomay AG, RiboPro

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/mrna-therapeutics-cdmo-global-market-report

Which Region Shows The Highest Potential For Future Expansion In The mRNA Therapeutics CDMO Market?

North America was the largest region in the mRNA therapeutics CDMO market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mrna therapeutics cdmo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The mRNA Therapeutics CDMO Market Report:

https://www.thebusinessresearchcompany.com/customise?id=25841&type=smp

Browse Through More Reports Similar to the Global mRNA Therapeutics CDMO Market 2025, By The Business Research Company

Mrna Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/mrna-therapeutics-global-market-report

Mrna Cancer Vaccines And Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/mrna-cancer-vaccines-and-therapeutics-global-market-report

Peptide And Oligonucleotide Cdmo Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/peptide-and-oligonucleotide-cdmo-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795